1201 suspected adverse reactions to Covid-19 vaccines have been reported.



[ad_1]

IWT notes that in the first month of vaccination, people were vaccinated with two vaccines that were on the Lithuanian market at the time. The third vaccine started in early February. The number of IR reports received during the entire vaccination period is 0.5 percent of the vaccine doses used, according to the IWT report.

Since the start of vaccination, 729 notifications have been received for Comirnaty, 61 notifications for COVID-19 Vaccine Moderna, and 401 notifications for COVID-19 Vaccine AstraZeneca. The name of the vaccine was not provided in the 10 RNA reports received.

The IUDC reports that during the second month of vaccination, it received 890 initial reports of NSAIDs in Lithuania related to the use of COVID-19 vaccines. There were 432 reports of CNS after Comirnaty administration, 48 reports of CNS after the COVID-19 Vaccine Moderna vaccine, and 401 reports of COD after the COVID-19 AstraZeneca vaccine.

The name of the vaccine was not mentioned in 9 RNA reports. Sudden deaths of two elderly patients were also reported during the second month of vaccination. Both cases were assessed as unrelated to vaccination.

868 messages are classified as mild to moderate and 22 as severe. Women reported more CNS reports than men, 817 and 73 reports, respectively. The age limits for CIS reporters are 19 to 87 years old. The number of reports received from health professionals is 86, from patients – 799; 5 notifications received from the Eudravigilance database.

The main reports received by the Office of People Vaccinated against COVID-19 were fever, headache, muscle aches, nausea, and injection site reactions. The most common of these reactions was mild to moderate and resolved within a few days.

The SCCP recalls that the Summary of Product Characteristics and the package insert for registered COVID-19 vaccines include recommendations and precautions to be followed by healthcare professionals and patients to use the vaccines safely and effectively.

As with all medicines, data on vaccine use is constantly monitored. Every COI report for COVID-19 vaccines received by ICD is carefully evaluated and all necessary steps are taken to protect patients.



[ad_2]